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Abstract
Background: Research shows that more than half of the people taking medication for a chronic condition are
non-adherent. Nonadherence hinders disease control with a burden on patient quality of life and healthcare
systems. We developed a tool that provides insight into nonadherence risks and barriers for medication-adherence
including an intervention strategy to overcome those barriers. This study aims to assess the effectiveness of using
this adherence tool in starters with cardiovascular or oral blood glucose-lowering medication to improve
medication-adherence.
Methods/design: In a cluster-randomized controlled trial 25 pharmacies in the Netherlands will be randomized to the
intervention or control arm. Patients registered in a general practice participating in a collaborative can be included
when they start cardiovascular or oral blood glucose-lowering medication prescribed by their general practitioner.
Participants complete an assessment consisting of measuring nonadherence risk and potential barriers to adherence.
For patients with an increased nonadherence risk, a graphic barrier profile is created, showing to what extent eight
cognitive, emotional, or practical barriers are present.
All patients will fill in the medication-adherence assessment twice: between 1 and 2 weeks after the start of the
medication and after 8 months.
The intervention strategy consists of discussing this barrier profile to overcome barriers. Pharmacists and assistants of
the intervention pharmacies are trained in discussing the profile and to offer a tailored intervention to overcome
barriers. In the control arm, patients receive care as usual.
The primary outcome is medication-adherence of patients with a high risk of nonadherence at 8 months follow-up.
Secondary outcomes include the difference in the percentage of patients with an increased nonadherence risk
between intervention and control group after 8 months, the predictive values of the baseline questionnaire in the
control group in relation to medication-adherence after 8 months, medication-adherence after 1 year follow-up, and
barriers and facilitators in the implementation of the tool.
Discussion: This manuscript presents the protocol for a cluster-randomized clinical trial on the use of an adherence
tool to improve medication-adherence. This study will provide insight into the effectiveness of the tool in starters with
cardiovascular or oral blood glucose-lowering medication in improvement of medication-adherence.
Trial registration: The Netherlands National Trial Register, NTR5186. Registered on 18 May 2015.
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Background
Adherence to chronic medication is problematic in clin-
ical practice. Nonadherence leads to poor disease control
with a burden on patient quality of life and healthcare
systems [1]. Research shows that, on average, 50 % of pa-
tients with a chronic condition are not adherent, with
adherence estimates ranging from 17 to 80 % [2–4].
Drugs for asymptomatic chronic conditions are found to
have especially low adherence rates [5]. In several stud-
ies, the risk for nonadherence was shown to be highest
in the first year after the start with chronic medication
[6, 7]. Consequently, interventions to warrant adherence
are expected to be most effective at the initiation of a
chronic medication treatment.
Various causes have been demonstrated to hamper
adherence [4, 8]. Conventional models distinguish between
intentional and nonintentional barriers as causes for poor
adherence [9]. Intentional barriers develop because of pa-
tients’ beliefs and perceptions about their medications and
diseases. These barriers can be further subdivided into cog-
nitive and emotional barriers. Nonintentional barriers de-
pend on capacity, resources, and practical barriers [10].
Besides personal beliefs, adherence depends on the type of
disease but may also vary within patients over time [10].
The multifaceted nature of the adherence problem illus-
trates that improving adherence is complex and needs in-
terventions tailored to the individual patient [9]. A recent
Cochrane review showed that current methods of improv-
ing medication adherence for chronic health problems are
mostly complex and not very effective [11]. The effective-
ness of nonadherence interventions can be improved by
targeting the underlying barriers related to nonadherence
for a specific patient. Interventions can focus on cognitive
and emotional barriers (intentional nonadherence) or on
practical barriers (nonintentional nonadherence), each with
their own specific intervention ingredients tailored to pa-
tients’ needs. Depending on the character of the interven-
tion, different primary healthcare providers can be
involved. For instance, the pharmacist may be better
equipped to implement aids to overcome practical barriers,
and general practitioners (GPs) and nurses may be better
able to help the patient overcome cognitive and emotional
barriers. Though there are several instruments assessing
actual medication adherence and various programs to im-
prove adherence, at present, no tool is available for health-
care providers to predict the risk and potential causes for
nonadherence at the start of chronic medication with a tai-
lored approach to overcome the individual barriers de-
tected. Such a tool would enable them to address potential
barriers to nonadherence and prevent early cessation of
chronic medication. Therefore, a predictive tool is needed
at the start of chronic medication to assess the risk of fu-
ture nonadherence and to address the assessed causes of
the nonadherence for a patient at high risk.
Furthermore, an implementation strategy is needed to
provide tailored interventions in primary healthcare set-
tings. For the efficient implementation of effective inter-
ventions in existing primary healthcare workflows, a
good cooperation between pharmacists, GPs, practice
nurses, and assistants is required. Technology-based sys-
tems that enable easy communication between health-
care providers about the progress of interventions and
agreement about the allocation of time and resources
need to be in place.
At Philips Research, a questionnaire was developed
that creates a barrier profile based on an online
assessment. The questionnaire consists of two parts: the
Probabilistic Medication Adherence Scale (ProMAS),
which is an 18-item questionnaire to assess nonadher-
ence risk [12], and an additional 23 questions that assess
the underlying barriers related to nonadherence. The
resulting barrier profile provides insight into the extent
to which eight cognitive, emotional, and practical bar-
riers may hamper a patient’s adherence. For each of the
identified barriers, a set of recommendations was formu-
lated in a manual for healthcare providers on how to ad-
dress the barriers in an intervention. Consequently, in
patients starting chronic medication and at high risk for
nonadherence, as assessed by ProMAS, the barrier pro-
file provides an intervention strategy to overcome cogni-
tive, emotional, and practical barriers to adherence at an
early moment and thereby promotes adherence.
The primary objective of this study is to assess the
effectiveness of using the medication-adherence tool in
starters with cardiovascular medication, which includes
antiplatelets, antihypertensives, and lipid-lowering drugs
(Appendix), and oral blood glucose-lowering medication
in the improvement of medication adherence as mea-
sured by pharmacy dispensing data. A second objective
is to evaluate the implementation strategy to reduce bar-
riers identified in patients at risk for nonadherence for a
primary care setting relating to the acceptability of the
workflow for all stakeholders (pharmacists, general prac-
titioners, and patients).
The primary research question is as follows:
1. What is the benefit of using the medication-adherence
tool for medication adherence of patients starting
with cardiovascular or oral blood glucose-lowering
medication identified as being at high risk for
nonadherence at a follow-up of 8 months
compared to usual care?
Secondary questions are as follows:
1. a) What is the association between the ProMAS
score at 8 months and the adherence after
8 months?
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b) To what extent can the identified barriers at
8 months predict medication adherence after
8 months?
2. What are the predictive values of the ProMAS score
and the barrier profile, measured at drug initiation,
in relation to medication adherence after 8 months
for all patients in the control group who started
with cardiovascular of diabetes medication?
3. What is the adherence of the subgroup of patients
with a longer follow-up period of at least 1 year after
drug initiation?
Process evaluations will address the following question:
1. What are the barriers and facilitators, as experienced
by pharmacists and patients, regarding the
implementation of the medication-adherence tool
in their daily practice?
The aim of this study protocol is to describe the design
and methods of a study to assess the effectiveness of using
a medication-adherence tool in starters with cardiovascular
or oral blood glucose-lowering medication to improve
medication adherence.
Methods/design
Study design
This study is a cluster-randomized trial with an interven-
tion group of pharmacies (using the adherence tool) and a
control group of pharmacies (providing usual care). The
key components of the medication-adherence tool are de-
scribed in Table 1.
As in daily practice, patients receive a new medication
from their community pharmacist; therefore, the assess-
ment of patients’ medication adherence and potential bar-
riers was most appropriately situated in the community
pharmacy for our study. In the Netherlands, patients with
a first dispensing of a chronic drug usually receive only an
amount for 2 weeks. Treatment is continued after 2 weeks
according to the experiences of the patient. Thus, patients
starting with the study medication will have to have con-
tact with the community pharmacy within approximately
2 weeks. This makes it convenient to ask eligible patients
to participate in the study at the first dispensing, let them
fill in the medication adherence assessment before the
second dispensing, and apply the intervention when
necessary at the second dispensing. The feasibility of
implementing the use of the adherence tool in the daily
pharmacy workflow was piloted in two pharmacies. Dur-
ing the pilot period, researchers regularly contacted the
pilot pharmacists in order to track their experiences and
any developments and to solve any issues. After the pilot
period, a meeting between the research team and the two
pilot pharmacists was planned for evaluation of the pilot.
Based on the experiences during the pilot period, work-
flow adaptations leading to an increase in convenience
and efficiency were made. Small changes in study informa-
tion for patients, pharmacists, and GPs were made after
the pilot period.
For further clarification of this study protocol, we ref-
erence the study flow diagram (Fig. 1) and the SPIRIT
checklist (Additional file 1).
Recruitment of pharmacies, general practices, and
patients
The trial will be carried out with pharmacists, general
practitioners, and their patients with a first prescription
of cardiovascular medication, including antihypertensives,
antiplatelets, and lipid-lowering drugs, or oral blood
glucose-lowering medication made by their GP within the
study period (see Appendix for drug classes and ATC
codes). A first prescription is defined as no drug dispensing
from a drug class issued to the patient in the preceding
year. For example, a patient who used a beta-blocking agent
in the preceding year is not eligible when starting another
beta blocker but will be eligible when starting a statin.
The primary care cooperation De Ondernemende
Huisarts (DOH), or The Innovative General Practi-
tioner, will play a key role in the recruitment of phar-
macies and general practices for this study. DOH is a
general practice collaborative, i.e., approximately 70
GPs working in 16 group practices in the southeastern
part of the Netherlands who that share an overarching
management structure and develop and implement
Table 1 Components of the medication-adherence tool
■ Online questionnaire consisting of two parts
a) the Probabilistic Medication Adherence Scale (ProMAS), slightly
adapted for use with patients with a first prescription of
cardiovascular or oral blood glucose-lowering medication
b) assessment of the underlying barriers related to nonadherence
■ Tools used by pharmacists to facilitate the provision of a tailored
intervention
a) a 3-hour training session on patient-centered communication and
discussion of the barrier profile
b) manual containing instructions for discussing and overcoming the
various potential barriers for medication adherence
c) an internet-connected tablet to register new participants, to review
the graphical barrier profile at the time of the second dispensing,
and to make any notes regarding the conversation and applied
intervention
■ Tailored intervention
As the second dispensing, a tailored intervention is initiated for patients in the
intervention group with an increased risk for nonadherence. All interventions
start with a discussion of the patient’s barrier profile. The intervention will be
tailored to the identified emotional, cognitive, and practical barriers of the
patient.
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structured care for several prevalent chronic condi-
tions, including cardiovascular diseases and diabetes.
Pharmacies
The DOH cooperates closely with a number of commu-
nity pharmacies (so-called CaZo cooperation). In total, 25
pharmacies have joined the cooperative. A representative
of DOH will contact all 25 pharmacies connected to the
DOH cooperation and provide them an invitation and an
information leaflet about the study. Three members of the
research team will visit all pharmacists who express their
intention to participate. After a detailed explanation of the
study aims, methods, and expected outcomes to the phar-
macists, written informed consent for both participation
and collection of de-identified patient data from the phar-
macist’s database will be obtained.
The participating pharmacies are randomized for the
intervention or control group, which implies that the
patients are clustered within pharmacies. Pharmacies
are stratified into small or large depending on their
number of patients registered with DOH GPs. After
the randomization procedure (drawing from a hat by
an independent research assistant and consecutive al-
location) has been performed, the pharmacies will be
informed of their assignment to either the interven-
tion group or the control group. Only pharmacists and
pharmacy assistants from the intervention group are
being trained to interpret the barriers to adherence
profile and to provide tailored care. This prevents contam-
ination between the intervention and control patients.
Because patients in the Netherlands predominantly visit
one pharmacy for all their medication, pharmacists are
assumed to have complete medication dispensing infor-
mation for their patients [13].
Due to the test of the medication-adherence tool, both
pilot pharmacies will have to participate in the interven-
tion group.
General practices
Participating DOH general practices will receive written
information on the study. GPs will be asked to give written
informed consent to participate in the study and to share
patient information from their electronic medical record
system They will be encouraged to contact a member of the
research team with their questions if anything is unclear.
Patients
Inclusion criteria Patients will be eligible for the trial if
all the following criteria are met: age > 18 years, being
prescribed a cardiovascular or glucose-lowering drug for
the first time by a DOH GP. The pharmacist will be sig-
naled by his computer system when a patient visits with
a first prescription.
Exclusion criteria Patients will be excluded if they have
any cognitive impairments or insufficient Dutch lan-
guage skills as determined by the pharmacists' judgment.
Inclusion numbers will be monitored; inclusion will be
stopped when the targeted number is reached.
Outline of the study procedure for patients
For all patients starting with cardiovascular or oral blood
glucose-lowering medication with a first prescription
from a DOH GP, the GP starts a treatment plan in the
electronic patient information system that the GPs and
pharmacies use in their current daily practice. Then, the
following process starts when the patient comes to the
pharmacy for the first dispense.
1. On first dispensing at the pharmacy, when the
pharmacist considers the patient eligible for
participation, the patient receives a short oral
introduction to the study and an invitation to
participate in the study.
Fig. 1 Flow diagram of the study
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2. When the patient is interested in participation, the
pharmacist asks for the patient’s permission to send
the patient an email with a link to the study survey
and collects the patient’s Citizen Service Number
(CSN). Additionally, the pharmacist makes an
appointment for the second dispense.
3. The pharmacist (assistant) uses a tablet/web
browser to register the patient for potential
enrollment in the study.
4. One week after the pharmacy visit, the computer
system sends an email to the patient containing the
link to the questionnaire.
5. Then, the patient receives a paper-based package of
study information and consent form to take home.
This information will be provided on top of the
usual information given during the first dispense in
the pharmacy and will not replace any information
that is usually provided during the first dispense.
6. At home, the patient reads the study information and
decides on participation. If the patient decides to
participate, (s)he answers the link in the email received
and completes the survey. The answers are used to
produce a profile, which is sent to the electronic
patient file system so that the pharmacists of the
intervention practices have it available during the
second dispensing appointment when the intervention
starts (For control patients, the profile is only made
available after completion of the study). The survey
answers are retained until the end of the study.
7. The patient sends the signed informed consent
forms by regular mail in a pre-stamped envelope.
For the second dispensing at the pharmacy, the
pharmacists in the control arm do not receive the
results of the medication adherence assessment from
their patients, and they provide usual care. This
includes the usual information at the start of a new
drug as described in the guidelines of the pharmacists’
profession (KNMP richtlijn ‘ter hand stellen’, http://
www.knmp.nl/praktijkvoering/bekostiging/
begeleidingsgesprek-nieuw-geneesmiddel/knmp-
richtlijn-ter-hand-stellen-juni-2013).
8. The pharmacist in the intervention group checks
whether the patient has completed the medication
adherence assessment and takes care to provide a
second dispensing of the drug.
9. If the patient has not completed the assessment at the
moment of the second dispensing, the patient is asked
whether (s)he would like to participate and is asked to
complete the survey in the pharmacy on a tablet.
Patients that prefer to participate with a paper-based
questionnaire instead of an online questionnaire can sign
and send in the paper informed consent form and indi-
cate their preference. They will receive the questionnaire
per regular mail together with a return envelope. Those
participants that fill out a paper-based questionnaire
return the questionnaire by regular mail, and their data
will be entered into the system by a research worker. As
an alternative, participants who prefer the online ques-
tionnaire but do not have access to a computer or Internet
at home can fill out the questionnaire at the pharmacy
during their visit for the second dispensing.
At the second dispensing moment, pharmacists in the
intervention group will initiate a tailored intervention
for patients with an increased risk for nonadherence.
The intervention will be tailored to the patient’s emotional,
cognitive, and practical barriers, as identified by the barriers
assessment. Patients without an increased risk for nonad-
herence, receive usual care (delivery of medication only).
As mentioned above, the ProMAS scores and profiles will
be stored in the electronic patient information system.
The intervention
In the pharmacy, the pharmacist will intervene at the
second dispensing for those patients with a PROMAS
score that signals an increased nonadherence risk. In the
intervention pharmacies, the barrier profile (see Fig. 2),
in combination with the manual, will be used as a sys-
tematic decision support tool to tailor interventions to
the identified cognitive, emotional, and practical adher-
ence barriers. The manual serves as a guideline for dis-
cussing the identified barriers and determining an
intervention to address them. Table 2 describes two ex-
amples of barriers with recommendations from the man-
ual on how to address these barriers and to choose an
intervention. In the barrier profile, the extent to which
each of the eight potential barriers are present will be
depicted graphically in three gradations (see Fig. 2).
All interventions start with a discussion of the barrier
profile with the patient in a manner that makes use of the
patient-centered techniques. When cognitive or emotional
barriers (e.g., attitude with regard to medication, concerns
about medication usage, and fear of side effects) are present
for the specific patient, the pharmacist starts to discuss the
relevant issues in the profile using the recommendations of
the manual and the patient-centered communication tech-
niques to try to take away or diminish these barriers. The
manual proposes the following main intervention strat-
egies: for patients with an insufficient awareness of the need
to use the medication, self-assessment of clinical measures
(blood pressure and blood glucose) will be proposed, since
this has been shown to increase medication adherence.
When agreed on by the patient, this will be initiated in the
pharmacy by providing the patient the relevant devices.
When barriers mainly appear to be practical for the spe-
cific patient (inconvenience and/or knowledge about
medication scheme), the pharmacist offers one or several
practical solutions, e.g., suggestion for medication change,
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pill organizer, use of a Baxter system, reminders, seek the
help of the patient’s social network, or simplification of
dosage scheme. The pharmacist registers the intervention.
Since the pharmacist as well as the GP and the nurse
practitioner are involved in supporting their patient
with their medication use, a good communication and
cooperation among all these parties is needed.
Technology-based systems that enable easy communica-
tion between healthcare providers about the progress of
interventions and agreement about allocation of time and
resources are required for optimal functioning of the
medication-adherence tool. The chain information system
Care2U is the preferred way to communicate all informa-
tion about the interventions. Currently, the system needs
some adaptations in order to enable such communication
between pharmacy and general practice. In case such
communication is not possible by the time of the start of
the study, other ways of communication (telephone, email,
or fax) between pharmacists and GPs will be agreed upon.
Implementation of the medication-adherence tool
To deliver the tailored intervention, training on a patient-
centered communication technique will be offered to the
pharmacists, and one of the pharmacy assistants of the phar-
macies assigned to the intervention group. Intervention
pharmacists and their pharmacy assistants will receive a
three-hour training session before starting the trial, consist-
ing of a brief introduction to the proposed communication
technique, demonstration of a second dispense moment
with a barrier profile, and skills practice using role play. The
pharmacists and pharmacy assistants will be specifically
instructed on discussing the profile with the patients in
order to offer a tailored intervention to overcome cognitive,
emotional, or practical barriers.
Intervention pharmacies will also receive a manual con-
taining instructions for discussing and overcoming the vari-
ous potential barriers for medication adherence. In this
manual, potential barriers are categorized into cognitive,
emotional and practical nonadherence barriers. Further-
more, intervention pharmacies will receive a follow-up
group session from the trainer on the patient-centered com-
munication technique to provide support and exchange ex-
periences on discussing the barrier profiles. In addition,
three members of the research team will visit all participat-
ing pharmacists. At least the pharmacist and one experi-
enced pharmacy assistant of a pharmacy will be present
during that appointment. We will explain the study in detail
and provide them with an easy-to-understand explanation
of the workflow concept and subsequently discuss how the
workflow concept can be optimally tailored to existing rou-
tine work procedures in the pharmacy. One of the re-
searchers will be available during working hours to answer
questions arising from the study. Finally, pharmacists will be
offered the opportunity to contact one of the pilot pharma-
cists to ask questions and advices about the study proce-
dures. Table 3 summarizes the various elements of the
implementation strategy.
Measures
ProMAS
The Probabilistic Medication Adherence Scale (ProMAS) is
an 18-item validated questionnaire to assess nonadherence
behavior in general [12]. For the purpose of this study, the
questionnaire will be slightly adapted for use with patients
who do not take any other chronic medication and who
Fig. 2 Example of a barrier profile. The profile shows eight potential adherence barriers: two emotional barriers (feelings with regard to medication
and fear of side effects); one emotional/cognitive barrier (concerns about medication usage); two cognitive barriers (necessity beliefs and attitude
with regard to medication); one cognitive/practical barrier (self-efficacy), and two practical barriers (inconvenience and knowledge about
medication scheme)
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have a first prescription of cardiovascular or oral blood
glucose-lowering medication. The cut-off value for being at
risk for nonadherence is 13: patients with a score of ≥ 13
are considered to have an increased risk for nonadherence,
whereas patients with a score below 13 are not at risk for
nonadherence. The ProMAS will be applied at baseline and
at 8 months follow-up.
Scale on underlying barriers related to nonadherence
This questionnaire measures to what extent the following
emotional, and practical barriers for nonadherence are
present: feelings with regard to medication, fear of side
Table 2 Examples of recommendations on how to address the barriers in an intervention
■ In case “fear of side effects” seems to be a barrier
○ Ask questions to try to find the cause(s) for de fear of side effects and identify the influence of external factors such as media and other persons.
○ Focus on the elimination of the fear, using the following possibilities:
- explain that the medication can cause side effects and provide the patient information about the “number needed to harm,
- discuss the balance between the risk for side effects and the desired effect,
- discuss the best way for medication intake to prevent side effects, and
- agree about the intake of the medication and encourage the patient to report existing side effects.
Examples of questions:
○ How do you generally think about the fact that you need to take medication?
○ What is your attitude toward medication, and toward the prescribed medication in particular?
○ What information did you get about the benefits of the medication?
○ For which side effects do you have fear and where does it come from?
○ Did this fear always exist or did it change? What caused this change?
○ How does this fear influence you? What is the effect on your medication intake?
○ Do you have information on your risk for particular side effects?
○ Which side effects play a major role in your well-considered decision on the intake of this medication?
○ Which side effects do you expect, and to what extent do they prevent you from medication intake?
○ Let’s go through the information leaflet to discover which side effects can possibly occur in your case.
■ In case “knowledge about medication scheme” seems to be a barrier:
○ Discuss the prescribed use of the new medication.
○ Discuss the use of other chronic medication and assimilate the new medication into the patient’s medication scheme.
○ Take the patient’s customs into account.
○ Explain the importance of regular medication intake for the efficacy of the medication and the possible side effects and
interaction with other medication.
○ Choose the most appropriate option for the patient:
- consider whether medication synchronization or a repeat prescription service will be helpful for the patient,
- consider reminders for medication intake,
- consider the use of a pill box at the start of each week with all medications,
- consider streamlining medication regimens and the development of a new treatment plan, and
- consider to involve an informal caregiver.
Examples of questions:
○ Do you have sufficient knowledge about your new medication scheme including all your medication?
○ Is this medication scheme feasible for you?
○ Do you need any support with regard to your medication intake?
Table 3 Elements of the implementation strategy
■ Visit of the pharmacy by the research team to provide the manual
and to tailor the workflow concept to existing work procedures in
an optimal way
■ Training session for pharmacists on patient-centered communication,
using the manual and discussing the barrier profile
■ Follow-up group session of the trainer on discussing the barrier profile
■ Onsite support on the use of the tablet
■ Availability of researcher for answering questions about the study
■ Possibility to contact pilot pharmacist for questions and advice on
study procedures
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effects, concerns about medication usage, necessity beliefs,
attitude with regard to medication, self-efficacy, incon-
venience, and knowledge about medication scheme.
Adherence
Medication adherence is calculated as the percentage of
days covered by medication (PDC) based on pharmacy
dispensing of one drug group since the start of the therapy
until the end of the study period. Patients with a PDC of
at least 80 % are labeled as “sufficiently adherent.” PDCs
are calculated per medication group (see Appendix), ex-
cept for blood glucose lowering drugs. As for diabetes,
often, more than one drug is used, and patients have to
adhere to each drug from the subclass, e.g. to biguanides
and sulfanilamide derivatives. Data on dispensing will be
based on routine pharmacy data collection.
Outcomes
The primary outcomes are as follows:
1. The primary outcome is the difference in the
medication adherence of patients with an initial high
risk of nonadherence between the intervention and
the control group, measured by pharmacy
dispensing records at 8 months follow-up.
The secondary outcomes are as follows:
1. Based on data from all patients participating:
(a)The difference in the percentage of patients with
an increased risk for nonadherence based on the
ProMAS between the intervention and control
group at 8 months follow-up
(b)The difference in percentage of patients with an
increased risk for nonadherence based on the
barrier profile between the intervention and
control group at 8 months follow-up
2. The positive and negative predictive values of the
ProMAS score and the barrier profile measured at
drug initiation in the control group in relation to
medication adherence at 8 months follow-up
3. Difference in medication adherence in the subgroup
of patients with a follow-up period of at least 1 year
after drug initiation. This in fact means to assess an
effect after a longer follow-up period of at least a
year analogous to the primary outcome.
The process evaluation will address the following:
1. The barriers and facilitators in the implementation
of the use of the medication-adherence tool.
These influencing factors will be discussed with all
pharmacists in the intervention arm by semistructured
interviews. The assessment on barriers and facilitators
will be based on the Tailored Implementation for
Chronic Diseases’ (TICD) checklist. This is a compre-
hensive, integrated checklist with 57 potential determi-
nants of practice grouped in seven domains: guideline
factors, individual health professional factors; patient
factors; professional interactions; incentives and re-
sources; capacity for organizational change; and social,
political, and legal factors [14].
Patients will also be interviewed about their experiences
with the medication adherence assessment and inter-
ventions. Informed consent for these interviews will be
obtained. Interviews will aim at gaining a better under-
standing of how patients and healthcare providers have
experienced the intervention in terms of effort, time in-
vestment, and benefits. The purposive patient sample
size will be determined based on theoretical saturation
(data collection until no new information is obtained).
Therefore, data review and analysis will be done in con-
junction with data collection.
Sample size
For the sample size calculation, the following assump-
tions are made: we assume that a percentage of 60 % is
nonadherent in our sample of patients at high risk based
on their ProMAS score. This assumption is reasonable
according to published studies [6]. We assume that the
intervention will increase the 80 % PDC in the intervention
group by 20 % compared to the control group. As patients
are clustered within pharmacies, the evaluation will be per-
formed by multilevel analysis to adjust for clustering. For
the effect of clustering, an intracluster correlation (ICC) of
0.05 was assumed.
In agreement with conventional power calculations, a
power of 80 % to detect a true difference and a chance
of 5 % of a type 1 error to wrongly conclude on a differ-
ence are assumed. For this trial, in the DOH/CAZO set-
ting, we assume that there are at least 14 community
pharmacies willing to participate. The sample size calcu-
lation results in 39 patients needed per pharmacy. PASS
software version 11 was used to determine the appropri-
ate sample size. Considering 30 % lost to follow-up dur-
ing the study period, 56 patients need to be included per
pharmacy to achieve the power needed. If only 50 % of
the patients agree to join the study, 112 patients need to
be invited per pharmacy.
In the potentially participating 25 pharmacies, a total
of at least 6,081 single patients with primary dispensings
of cardiovascular or oral blood glucose-lowering medica-
tions were detected within 12 months (as observed in
historical data). This means that, on average, 20 subjects
started with cardiovascular or oral blood glucose-lowering
medication monthly per pharmacy. Assuming 40 % of the
starters at risk for nonadherence (determined by a ProMAS
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score ≥ 13), this means, on average, that eight patients are
available monthly per pharmacy for an intervention. The
period to have 112 starters on cardiovascular or blood
glucose-lowering medication per pharmacy will be approxi-
mately 14 months.
A measurement period of at least 8 months is preferred in
order to get valid information from dispensing data. A first
prescription is usually dispensed for 14 days, followed by a
prescription for 90 days. After 8 months, at least two repeat
prescriptions after the second dispensing must have had oc-
curred to meet a PDC of 100 %. As we assume a PDC of
80 % is sufficient, at least (14 days + 180 days =) 196 days *
1.2 = 234 days = 7.8 months are needed to detect nonadher-
ence. If the last patient was included after 14 months, to-
gether with the measurement period, this ends up the total
study period with 22 months needed for follow up.
Data analysis
The primary analysis will be an intention-to-treat analysis
to test whether patients starting with cardiovascular or oral
blood glucose-lowering medication who are at high risk for
nonadherence and who received a tailored intervention
based on the patient’s identified emotional, cognitive, and
practical barriers will be more adherent compared to
patients who did not receive the intervention, expressed as
PDC. We will compare differences in medication adher-
ence between the intervention and control group both as a
dichotomous (PDC < 80 % versus PDC ≥ 80 %) and con-
tinuous outcome measure (mean PDC). Because patients
are clustered in pharmacies, we will perform multilevel
analyses, with adjustment for potential confounders
(patient age, gender, diagnosis, and number of medica-
tions). Secondary analyses will test the hypothesis that pa-
tients who received the tailored adherence intervention
will be more adherent compared to patients who did not
receive this intervention, expressed by the ProMAS score.
We will compare differences in the ProMAS score between
intervention and control group both as a dichotomous
(score < 13 versus ≥ 13) and continuous outcome measure
(mean score). To assess differences between groups, we
will perform linear and logistic mixed models. Further sec-
ondary analyses will assess the frequency of different bar-
riers for medication adherence. We will compare
differences in the profile score between intervention and
control group both as a dichotomous (per barrier, present,
or absent) and continuous (mean number of barriers
present) outcome measure. Finally, the predictive values of
the ProMAS score and the score on the eight identified
barriers on patient adherence, based on dispensing data,
will be quantitatively assessed. All statistical analyses
will be performed using SPSS software (version 20, IBM
Corp.) or MLWIN (version 2.28, University of Bristol).
We will qualitatively analyze the interviews with phar-
macists and patients. The interviews will be transcribed
verbatim. The transcripts will be analyzed by open cod-
ing at macro level using predefined main codes. After
the open coding, the research team will group themes
and subthemes for each level of healthcare. The program
Atlas.ti (version 6, ATLAS.ti Scientific Software Devel-
opment GmbH) will be used for analysis.
Steering committee
Five of the authors (JL, LB-vdH, AvH, MT, and JvL) to-
gether with a project leader from DOH and a pharmacist
form the steering committee. In weekly telephone confer-
ences, they closely follow the development of the study
with the possibility to make adjustments when necessary.
Discussion
This manuscript presents the protocol for a cluster-
randomized clinical trial on the effectiveness of an ad-
herence tool to improve medication adherence in starters
with cardiovascular or oral blood glucose-lowering medica-
tion. A trial provides an optimal design to elucidate the ef-
fectiveness of interventions tailored to the underlying
cognitive, emotional, and practical barriers to nonadher-
ence identified for the patient. The results will provide
insight in both the effectiveness of applying the medication-
adherence tool and the predicting value of the ProMAS
and the identified barriers for medication nonadherence.
The effect of interventions to increase adherence depends
on many factors. However, many approaches to improve
adherence apply the one-size-fits-all-principle. By discuss-
ing the barrier profile with the patient, pharmacists can
provide personalized support. An important and unique
component of this study is the provision of an intervention
tailored to the patient’s emotional, cognitive, and practical
barriers. Not only the intervention itself, but also the imple-
mentation of the intervention will be tailored. The research
team will visit all participating pharmacies to tailor the
workflow concept as much as possible to existing work pro-
cedures. As the information on the barriers and the inter-
vention is shared among the healthcare providers, all
information supplied to the patient is consistent. A limita-
tion of our study is that the questionnaire on barriers re-
lated to nonadherence has not been extensively used and
validated in earlier studies. Furthermore, randomization oc-
curs at the pharmacy level. Therefore, GPs may have pa-
tients in both the intervention and control group, which
could lead to contamination. However, the barriers are dis-
cussed with the patients in the intervention pharmacies
only. As the GPs will only follow a part of the interven-
tion from the implementation guide for those patients
that are announced by the intervention pharmacists,
this limitation is presumably not severe. This study will
be carried out in the DOH/CAZO care groups. These
care groups have innovative mindsets. Consequently,
the implementation of the intervention in other care
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groups might need additional guidance. Within these
care groups, recruitment bias may be caused by the re-
sponse of patients with certain characteristics, includ-
ing medication adherence. Due to privacy legislation,
the characteristics of nonresponders will not be
analyzed.
Trial status
At the time of submission of this study protocol, we are
recruiting pharmacies and patients for the trial.
Appendix
ATC codes for cardiovascular or oral blood
glucose-lowering medication
 ATC code A10B: oral antihyperglycemic drugs
 ATC code B01AC: platelet aggregation inhibitors
 ATC code C01A: cardiac glycosides
 ATC code C01D: vasodilators
 ATC code C03: diuretic drugs
 ATC code C07: beta-blocking agents
 ATC code C08: calcium channel blockers
 ATC code C09: agents acting on the
renin-angiotensin system
 ATC code C10: lipid-lowering drugs
Additional file
Additional file 1: SPIRIT checklist. (DOC 121 kb)
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